May 1, 2025

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer, President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Executive Officer, Vice President COO and CFO
Ryosuke Matsui
(TEL. 03-6214-3600)

GNI Group's view Regarding Gyre Therapeutics' Public Presentation

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. ("GNI") hereby provides its view regarding the presentation titled "Developing Anti-fibrotic Therapeutics for Chronic Organ Disease" ("the Gyre Presentation") disclosed by its core subsidiary, Gyre Therapeutics, Inc. ("GYRE"), on April 28, 2025 (U.S. time).

On page 16 of the Gyre Presentation, it is stated that the timing of the New Drug Approval (New Drug Application) submission in PRC for Hydronidone (F351) is expected to occur in the second quarter of 2025.

GNI views the topline data from Phase 3 clinical trial for F351 is expected to be received during the second quarter of 2025. Following the public disclosure of the results, we plan to conduct further data analysis, prepare the required submission materials, and proceed with the NDA filing. As stated on page 6 of the document titled "Business Plan and Growth Potential" disclosed on March 31, 2025, GNI's timeline view for the NDA submission remains unchanged, with the target timing being "two to three months after the disclosure of topline data."